Recombinant Human VEGF Receptors binding domains & Fc fragment Region (human IgG1) Protein
Product Sizes
1 mg
£746.00
YR0066-1MG
5 mg
£1442.00
YR0066-5MG
20 mg
£2835.00
YR0066-20MG
About this Product
- SKU:
- YR0066
- Additional Names:
- L-VEGF|MVCD1|VEGFA|VPF
- Application:
- Cell-based/Functional Assay
- Extra Details:
- What is research grade Aflibercept biosimilar? Research grade Aflibercept biosimilar has the same amino acid sequence as Aflibercept (trade name Eylea), a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors fused with the Fc region of human immunoglobulin gamma 1 (IgG1). It inhibits vascular endothelial growth factor (VEGF), and is used in the treatment of macular edema following Central Retinal Vein Occlusion (CRVO) and neovascular Age-Related Macular Degeneration (AMD). Aflibercept is a dimeric glycoprotein with a molecular weight of 96.9 kilo Daltons (kDa). Glycosylation adds its molecular weight to 115 kDa in total. Ziv-aflibercept (trade name Zaltrap) was developed as an injection for treatment of metastatic colorectal cancer.
- Formulation:
- Purified from cell culture supernatant in an animal-free facility
- Immunogen:
- VEGF
- Isotype:
- IgG1
- Molecular Weight:
- 115 kDa
- Purity:
- >95%
- Shipping Conditions:
- Blue Ice
- Storage Conditions:
- 2-8[o]C Avoid freeze/thaw cycles., -70[o]C Avoid freeze/thaw cycles.
- Supplier:
- ABclonal Technology
- Type:
- Proteins, Peptides, Small Molecules & Other Biomolecules: Recombinant Proteins
- Manufacturer's Data Sheet:YR0066
